ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,623.91
      0.93%
      US Tech 100
      19,134.20
      1.43%
      Dow Jones
      41,529.22
      0.23%
      Brent Oil
      70.70
      1.41%
      Bitcoin
      82,833.62
      -0.02%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Verve Therapeutics Inc (VERV)

      7. Verve Therapeutics Inc (VERV) News

      Verve Therapeutics Inc

      Verve Therapeutics Inc (VERV)

      Verbund Ag
      Verbund Ag
      Verbund Ag
      Verbund Ag
      6.505
      0.345
      ( 5.60% )
      Updated: 13:13:33
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      VERV News

      Official News Only

      Form POS AM - Post-Effective amendments for registration statement
      Edgar (US Regulatory)
      February 27 2025
      VERV (5.60%)

      Form S-8 - Securities to be offered to employees in employee benefit plans
      Edgar (US Regulatory)
      February 27 2025
      VERV (5.60%)

      Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
      Edgar (US Regulatory)
      February 27 2025
      VERV (5.60%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      February 27 2025
      VERV (5.60%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      January 10 2025
      VERV (5.60%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      January 10 2025
      VERV (5.60%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      January 10 2025
      VERV (5.60%)

      VERV Discussion

      View Posts
      Monksdream Monksdream 2 weeks ago
      VERV 10Q due Monday 2/24
      👍️0
      Monksdream Monksdream 7 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 7 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 7 months ago
      VERV 10Q due AUGUST5
      👍️0
      Monksdream Monksdream 8 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 8 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 9 months ago
      VERV more new lows up ahead
      👍️0
      Monksdream Monksdream 10 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 10 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 11 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 11 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 11 months ago
      VERV new 52 lo
      👍️0
      Firestorm22 Firestorm22 11 months ago
      uh oh
      👍️0
      Monksdream Monksdream 11 months ago
      VERV over $10
      👍️0
      fink fink 1 year ago
      Looking for an entry now
      👍️0
      Terpi Terpi 1 year ago
      Could see another nice move here is the 50 day holds into close.
      👍️0
      Monksdream Monksdream 1 year ago
      VERV morning rally
      👍️0
      TheFinalCD TheFinalCD 2 years ago
      https://cathiesark.com/
      👍️0
      crudeoil24 crudeoil24 3 years ago
      VERV IS A GREAT $$$$$ OPPORTUNITY.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Verve Therapeutics started at outperform with $48 stock price target at BMO Capital
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s initial two programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
      👍️0

      Your Recent History

      NASDAQ
      VERV
      Verve Therapeutics
      COIN
      VNLUSD
      Vanilla
      BIT
      O8JRG8
      Morgan Stanley BV
      BIT
      UC5LVN
      Unicredit Bank
      NYSE
      ETY
      Eaton Vance Tax Managed ...
      BIT
      NSCIT0538677
      Popolare Bari RMBS
      BIT
      NSCIT65410B4
      Republic of Italy
      BIT
      F37898
      Vontobel Financial Produ...
      NASDAQ
      PWOD
      Penns Woods Bancorp
      BIT
      UB8KNT
      Unicredit Bank
      BIT
      F37060
      Vontobel Financial Produ...
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads